August 30, 2018 Bio/Pharma/CRO Product Launch

Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Basel, 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in... Read more

August 28, 2018 Bio/Pharma/CRO PR/Corporate

Changes to the Roche Corporate Executive Committee

Basel, 28 August 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. Until a successor is named, Michael Heuer,... Read more

August 28, 2018 Uncategorized

Changes to the Roche Corporate Executive Committee

Basel, 28 August 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. Until a successor is named, Michael Heuer,... Read more

August 22, 2018 Chromatography Licensing, IP, and Legal PR/Corporate

Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer

Basel, 22 August 2018 Invitation to Roche’s Virtual Pipeline Event: Key data for Roche’s lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 25 September 2018, highlighting the results... Read more

August 20, 2018 Bio/Pharma/CRO

China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer

Basel, 20 August 2018 China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China, just eight and nine months after EMA and FDA approvals, respectively Supporting data showed Alecensa significantly reduced the risk of disease progression or death by... Read more

August 13, 2018 Acad, Gov/Utilities

FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies

Basel, 13 August 2018 FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies There are currently no FDA-approved treatments that help prevent severe reactions due to food allergies As many as 15 million Americans have food allergies – including approximately 6 million children – and the incidence is increasing Roche (SIX: RO, ROG;... Read more

August 3, 2018 Acad, Gov/Utilities

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

Basel, 03 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting... Read more

August 3, 2018 Acad, Gov/Utilities

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

Basel, 03 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting... Read more

July 31, 2018 PR/Corporate

Roche Purchases Shares in Tender Offer for FMI

Basel, 31 July 2018 Roche Purchases Shares in Tender Offer for FMI Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares... Read more

July 31, 2018 M&A, Partnerships

Roche Purchases Shares in Tender Offer for FMI

Basel, 31 July 2018 Roche Purchases Shares in Tender Offer for FMI Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares... Read more